Valuation: Adimmune Corporation

Market Cap 7.38B 231M 203M 187M 174M 329M 22B 335M 2.25B 872M 10.8B 869M 850M 37.59B P/E 2024
-34.7x
P/E 2025 -33.2x
Enterprise Value 7.99B 251M 220M 203M 189M 356M 23.83B 363M 2.44B 944M 11.7B 941M 921M 40.71B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.23%
Yield 2024 *
-
Yield 2025 -
1 day-0.57%
1 week+2.04%
Current month-0.57%
1 month+2.04%
3 months-4.63%
6 months-7.65%
Current year-7.65%
1 week 16.8
Extreme 16.8
17.8
1 month 16.8
Extreme 16.8
18.45
Current year 16.8
Extreme 16.8
21.5
1 year 15.95
Extreme 15.95
22.5
3 years 15.9
Extreme 15.9
38
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 20/06/2019
Director of Finance/CFO - 01/01/2021
Chief Tech/Sci/R&D Officer - 26/01/2022
Director TitleAgeSince
Director/Board Member - 20/06/2019
Director/Board Member - 15/08/2011
Director/Board Member - 29/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%+2.04%+5.42%-53.58% 233M
+0.19%+0.21%+16.79%-13.00% 63.44B
-1.56%+2.46%+54.48%+217.61% 56.98B
+0.36%+39.60%+39.60%+39.60% 41.58B
+3.16%+5.65%-50.57%-57.33% 38.01B
-2.93%+5.09%+61.25%-26.52% 31.9B
+3.53%+19.99%+152.70%-40.44% 27.79B
+0.40%+4.93%+65.59%+83.33% 22.65B
-0.56%+4.05%+1.53%+168.92% 17.64B
+1.34%+0.39%+62.46%+122.53% 16.49B
Average +0.29%+4.85%+40.92%+44.11% 31.67B
Weighted average by Cap. +0.24%+4.50%+39.89%+50.35%

Financials

2024 2025
Net sales 1.56B 48.85M 42.89M 39.48M 36.79M 69.38M 4.64B 70.79M 475M 184M 2.28B 183M 179M 7.93B 1.4B 43.97M 38.61M 35.54M 33.11M 62.45M 4.18B 63.72M 427M 166M 2.05B 165M 162M 7.14B
Net income -243M -7.62M -6.69M -6.16M -5.74M -10.82M -724M -11.04M -74.03M -28.68M -355M -28.6M -27.98M -1.24B -240M -7.53M -6.61M -6.08M -5.67M -10.69M -716M -10.91M -73.16M -28.35M -351M -28.26M -27.65M -1.22B
Net Debt 140M 4.38M 3.84M 3.54M 3.3M 6.22M 416M 6.35M 42.56M 16.49M 204M 16.44M 16.08M 711M 612M 19.21M 16.87M 15.53M 14.47M 27.28M 1.83B 27.84M 187M 72.35M 897M 72.13M 70.57M 3.12B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
01/07/26 NT$17.50 -0.57% 898,878
30/06/26 NT$17.60 +0.57% 968,618
29/06/26 NT$17.50 +4.17% 1,713,947
26/06/26 NT$16.80 -1.75% 1,618,148
25/06/26 NT$17.10 -0.87% 1,328,492
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock